Compare GSK plc (GSK) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs 3M Company — how do they compare? GSK plc trades at $46.63 (market cap $91.88B), while 3M Company trades at $161 (market cap $84.36B). The key difference: GSK plc and 3M Company are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and 3M Company for 169 Days on average.
| GSK | MMM | |
|---|---|---|
Market Cap | $91.88B | $84.36B |
Volume | 7,730,529 | 2,325,301 |
Sector | Health | Industrials |
52-Week High | $61.18 | $183.79 |
52-Week Low | $43.24 | $141.10 |
Typical Hold Time | 93 Days | 169 Days |
Enterprise Value | $111.88B | $93.58B |
Dividend Yield | 3.9% | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
3M (MMM) trades at $161.26, down 0.53% with a bearish technical signal despite strong Q2 2026 earnings beats. The company shows robust profitability with 82.77% ROE and 11.9% net margins, though revenue has declined from 2022 peaks. Analyst consensus is mixed with 48% buy ratings and a $191 price target, while recent news highlights operational improvements and litigation management progress.
The outlook balances strong fundamentals against technical weakness and consumer segment challenges. Investment opportunity lies in continued margin expansion and industrial growth, while risks include high debt levels, soft retail demand, and ongoing PFAS litigation costs that could pressure cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
